drugset / Trial / NCT05047939
Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol
RandomizedParallel-groupSingle-blindTreatment
Summary
This prospective, randomized, single-blinded study is designed to compare the recovery profile between propofol-based total intravenous anesthesia (TIVA) and remimazolam-based TIVA in patients undergoing thyroidectomy. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery. We hypothesize that remimazolam-based TIVA antagonized by flumazenil can significantly shorten the time from the end of anesthetic administration to eye-opening compared to propofol-based TIVA.
Timeline
- Start
- 2021-12-14
- Primary completion
- 2022-08-12
- Completion
- 2022-09-11
Outcome
Met primary endpoint
paper The remimazolam group showed significantly faster first eye opening time (2.3 [interquartile range, IQR: 1.8-3.3] min vs. 5.0 PMID 37131126 ↗
Publications
- Background Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD. Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology. Pharmacotherapy. 2016 Sep;36(9):1021-7. doi: 10.1002/phar.1806. Epub 2016 Sep 1.
- Lee HJ, Lee HB, Kim YJ, Cho HY, Kim WH, Seo JH. Comparison of the recovery profile of remimazolam with flumazenil and propofol anesthesia for open thyroidectomy. BMC Anesthesiol. 2023 May 2;23(1):147. doi: 10.1186/s12871-023-02104-1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Propofol | Small molecule | — | Intravenous |
| Subject | Remimazolam | Small molecule | — | Intravenous |
| Background | Flumazenil | Small molecule | 0.2 mg | — |
Indications
No indication recorded.